A randomized controlled phase ii trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (tnbc)

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 824-831

  Awada, A ^a   Bondarenko, I N ^b   Bonneterre, J ^c   Nowara, E ^d   Ferrero, J M ^e   Bakshi, A V ^f   Wilke, C ^g   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Dnipropetrovsk State Medical Academy   (Ukraine)

^c CENTRE OSCAR LAMBRET   (France)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f Kaushalya Medical Foundation Trust Hospital   (India)

^g MediGene AG   (Germany)

Author keywords

Activated tumor endothelial cells; Advanced disease; Cationic liposomes of paclitaxel; EndoTAG 1; Lipid embedded paclitaxel; Triple negative breast cancer

Indexed keywords

ENDOTAG 1; LIPID; LIPOSOME; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENDOTHELIUM CELL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; TRIPLE NEGATIVE BREAST CANCER; VOMITING; ADVERSE DRUG REACTION; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOTHELIAL CELLS; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; PACLITAXEL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84897087162     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu025     Document Type: Article

References (28)

1. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. The Oncologist 2011;00 (Suppl 1):1-11.
2. Bayraktar S, Glück S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 2013;138:21-35.
3. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis 2010;32:99-122.
4. Von Mickwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 2012;23 (Suppl 6): vi35-vi39.
5. Joeensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol 2012;23 (Suppl 6): vi40-vi45.
6. Lowery AJ, Kell MR, Glynn RW et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012;133:831-841.
7. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother 2005;6:1477-1491.
8. Bedard PL, DiLeo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010;7: 22-36.
9. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-1986.
10. Del Mastro L, Fabi A, Mansutti M et al. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer 2013;13:164.
11. Medioni J, Huchon C, Le-Frere-Belda MA et al. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: Improved prognosis in triple-negative tumors. Drugs R D 2011;11:147-157.
12. Schmitt-Sody M, Strieth S, Krasnici S et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003;9:2335-2341.
13. Abu Lila AS, Ishida T, Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res 2010;27:1171-1183.
14. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002;62:6831-6836.
15. Löhr JM, Haas SL, Bechstein WO et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized phase II trial. Ann Oncol 2012;23:1214-1222.
16. Eichhorn ME, Ischenko I, Luedemann S et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 2010;126:1235-1245.
17. Fasol U, Frost A, Buechert M et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol 2012;23:1030-1036.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-216.
19. Maisano R, Zavettieri M, Azzarello D et al. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline-and taxane-pretreated breast cancer patients: a phase II study. J Chemother 2011;23:40-43.
20. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (C/C) in metastatic triple-negative breast cancer (TNBC). ASCO Meeting Abstracts 2011; (abstr 1007).
21. Aogi K, Yoshida M, Sagara Y et al. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemother Pharmacol 2011;67:1007-1015.
22. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2- negative (triple-negative) breast cancer. Breast Cancer Res 2010;121:261-271.
23. Koshy N, Quispe D, Shi R et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010;19:246-248.
24. O'Shaughnessy J, Romieu G, Diéras V et al. Meta-analysis of patients with triplenegative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). 33rd Annual San Antonio Breast Cancer Symposium (SABCS), 2010 (abstr P6-12-03).
25. Danso MA, Blum JL, Robert NJ et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. ASCO Meeting Abstracts 2008; (abstr 1075).
26. Conlin AK, Hudis CA, Bach A et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). ASCO Meeting Abstracts 2009; (abstr 1006).
27. Lobo C,Lopes G,Baez O,et al. Final results of a phase I.I study of nab-paclitaxel,bevacizumab,gemcitabine as first-line therapy for patients with H.E.R2- negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:427-435.
28. Ribeiro JT, Macedo LT, Curigliano G et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 2012;23: 547-555.